FDA 483 - Keystone Heart Ltd - October 29, 2020

An FDA inspection of Keystone Heart Ltd in Tampa, FL, identified a significant issue regarding an investigational study. The firm failed to promptly inform the FDA about critical new information concerning their REFLECT study, specifically a pause and resumption of enrollment due to a Data Monitoring Committee decision. This indicates a failure in timely communication of significant study changes to the regulatory body.